RU2018132739A3 - - Google Patents

Download PDF

Info

Publication number
RU2018132739A3
RU2018132739A3 RU2018132739A RU2018132739A RU2018132739A3 RU 2018132739 A3 RU2018132739 A3 RU 2018132739A3 RU 2018132739 A RU2018132739 A RU 2018132739A RU 2018132739 A RU2018132739 A RU 2018132739A RU 2018132739 A3 RU2018132739 A3 RU 2018132739A3
Authority
RU
Russia
Application number
RU2018132739A
Other languages
Russian (ru)
Other versions
RU2786909C2 (ru
RU2018132739A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018132739A publication Critical patent/RU2018132739A/ru
Publication of RU2018132739A3 publication Critical patent/RU2018132739A3/ru
Application granted granted Critical
Publication of RU2786909C2 publication Critical patent/RU2786909C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
RU2018132739A 2016-03-31 2017-03-03 Связывающие белки и способы их применения RU2786909C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662316516P 2016-03-31 2016-03-31
US62/316,516 2016-03-31
PCT/US2017/020654 WO2017172260A1 (en) 2016-03-31 2017-03-03 Binding proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
RU2018132739A RU2018132739A (ru) 2020-04-30
RU2018132739A3 true RU2018132739A3 (cg-RX-API-DMAC7.html) 2020-09-02
RU2786909C2 RU2786909C2 (ru) 2022-12-26

Family

ID=

Also Published As

Publication number Publication date
MX2018011503A (es) 2018-11-09
TW201809011A (zh) 2018-03-16
AU2017241161A1 (en) 2018-09-20
US20250188174A1 (en) 2025-06-12
CN109715206B (zh) 2023-11-07
WO2017172260A1 (en) 2017-10-05
CA3016035A1 (en) 2017-10-05
MX2024011328A (es) 2024-11-08
TWI897070B (zh) 2025-09-11
JP7610541B2 (ja) 2025-01-08
AU2022224794B2 (en) 2025-07-03
BR112018068898A2 (pt) 2019-01-22
US10975154B2 (en) 2021-04-13
US20190092866A1 (en) 2019-03-28
KR102370762B1 (ko) 2022-03-04
JP2022088355A (ja) 2022-06-14
CO2018009995A2 (es) 2018-12-14
JP2019513018A (ja) 2019-05-23
MY194669A (en) 2022-12-12
AU2017241161C1 (en) 2026-03-12
AU2025234197A1 (en) 2025-10-16
PE20190126A1 (es) 2019-01-17
WO2017172260A8 (en) 2017-12-28
JP7021099B2 (ja) 2022-02-18
NZ785098A (en) 2025-09-26
TW202423985A (zh) 2024-06-16
CL2018002687A1 (es) 2019-05-10
JP2024156852A (ja) 2024-11-06
KR20180130524A (ko) 2018-12-07
SG11201807279QA (en) 2018-09-27
US10174119B2 (en) 2019-01-08
KR20220032645A (ko) 2022-03-15
IL261666A (en) 2018-10-31
US20220073627A1 (en) 2022-03-10
IL261666B1 (en) 2024-05-01
JP7901634B2 (ja) 2026-08-06
CN109715206A (zh) 2019-05-03
IL261666B2 (en) 2024-09-01
AU2017241161B2 (en) 2022-05-26
AU2022224794A1 (en) 2022-09-22
KR102630655B1 (ko) 2024-01-30
EP4778574A2 (en) 2026-07-22
NZ745635A (en) 2024-03-22
US12180289B2 (en) 2024-12-31
CN117986363A (zh) 2024-05-07
EP3436068A4 (en) 2020-01-15
EP3436068A1 (en) 2019-02-06
TWI815793B (zh) 2023-09-21
US20170306031A1 (en) 2017-10-26
PH12018501882A1 (en) 2019-01-28
RU2018132739A (ru) 2020-04-30

Similar Documents

Publication Publication Date Title
BR112019001667A2 (cg-RX-API-DMAC7.html)
BR112018068177A2 (cg-RX-API-DMAC7.html)
BR112019002665A2 (cg-RX-API-DMAC7.html)
BR112018004986A2 (cg-RX-API-DMAC7.html)
BR122020022459A2 (cg-RX-API-DMAC7.html)
BR112019001429A2 (cg-RX-API-DMAC7.html)
BR112017026947A2 (cg-RX-API-DMAC7.html)
BR212018070320U2 (cg-RX-API-DMAC7.html)
BR112019011044B1 (pt) Compostos de pirazol substituído, seu uso, e composição farmacêutica
BR112019008501B1 (pt) Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador
BR122022000560B1 (pt) Inibidor da aldosterona sintase, seu uso e seu processo de preparação, e composição farmacêutica
BR112019003570B1 (pt) Determinação de largura de banda do canal de controle
BR112019003116B1 (pt) Configuração de símbolo de rajada comum de uplink
BR112019001236B1 (pt) Método para executar uma função suplementar para uma consulta de linguagem natural apresentada a um aplicativo de orientação de mídia interativa
BR112018076493B1 (pt) Sistemas e métodos para detecção de posição de feixe de luz
BR112018073794B1 (pt) Partícula, método de geração da partícula, vacina ou composição farmacêutica
BR122026002520A2 (pt) Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno
BR112019006736A2 (cg-RX-API-DMAC7.html)
CN303635900S (zh) 抑菌除酫除臭机(rs-1101)
CN303605333S (zh) 互联网排号自助采集机
CN303595084S (zh) 热水袋(拳击熊)
CN303566606S (zh) 婴儿咬胶(奶瓶型)
CN303557325S (zh) 座椅(vip)
CN303623750S (zh) 呼吸机风道壳体组件
CN303540892S (zh) 戒指(比特箭之比翼齐飞恒久远)